Drug Profile
CSJ 137
Alternative Names: CSJ137Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Antianaemics
- Mechanism of Action Haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Iron deficiency anaemia
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Iron deficiency anaemia in Czech Republic (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Iron deficiency anaemia in Israel (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Iron deficiency anaemia in United Kingdom (IV, Infusion)